Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MKC-1 · 6 trials · 9 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Ovarian Cancer Patients |
| B | EXPERIMENTAL | Endometrial Cancer Patients |
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MKC-1 | DRUG | capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles |
| pemetrexed | DRUG | standard dosing of 500 mg/m2 infused every 21 days |
Inclusion Criteria: 1. Provide written informed consent (and HIPAA authorization for release of protected health information, as applicable) prior to any study related assessments. 2. Histologically confirmed epithelial ovarian cancer, primary peritoneal carcinomatosis, fallopian tube cancers, or e...
Top 20 of 92 competitors
MKC-1 is an investigational small molecule being developed for the treatment of advanced cancer, breast cancer, hematological malignancies, ovarian cancer, and pancreatic cancer. It has been studied in clinical trials for these oncology indications, though it remains in clinical development and is not approved by the FDA.
MKC-1 is being developed by CASI Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol CASI. The company has sponsored clinical trials evaluating MKC-1 in various cancer types.
MKC-1 is in Phase 1 clinical development. While some completed trials were Phase 2, the most recent trial listed is Phase 1. It is an investigational drug and has not received FDA approval. All trials for MKC-1 have been completed, with no active trials currently ongoing.
MKC-1 has been studied in four completed clinical trials. These include NCT00306631 for breast cancer, NCT00408226 for advanced cancer and non-small cell lung cancer, NCT00568646 for pancreatic cancer, and NCT00607607 for ovarian or endometrial cancer. All trials were conducted in the United States or Canada.
MKC-1 is not known to have any alternative names. It is a distinct investigational compound developed by CASI Pharmaceuticals. No other names for this drug have been reported in the clinical trial records.